Glucosamine – key area of research says new review of the evidence

Glucosamine-chondroitin continues to be an important area of research when it comes to osteoarthritis of the knee, hip and hand joints, says a recent review of the literature in Current Opinion in Rheumatology.
Key findings of the evidence published over an 18-month period highlight that there has been a sustained focus on glucosamine-chondroitin as a therapeutic agent in the medical management of osteoarthritis.
“It is a mind boggling notion that 250 million people across the globe are affected by knee osteoarthritis alone,” explains expert Allan C. Gelber from the Johns Hopkins University School of Medicine in the US. “Recent studies convey a continued focus on potential therapeutic benefit derived from a combination of glucosamine-chondroitin, and intrigue the reader with a focus on biologic therapy (ie tumor necrosis factor antagonist) for osteoarthritis, and with use of strontium ranelate as a newer agent with potential therapeutic benefit.”

Click here to read the original research.

Give it a try?
Special promotion: buy one Flexable 1500mg Sustained Release Glucosamine Tablets (pack of 30 tablets) and receive an additional two packs FREE*. Click here for more information.

*offer valid until 4th May 2015